Oricol
Commercial- Indications
- Colorectal cancer, Gastrointestinal diseases
Company intelligence / Profile preview
Origin Sciences develops innovative diagnostic devices and assays for the detection, diagnosis, and monitoring of gastrointestinal diseases. Their flagship product is the Oricol™ sample collection device, which enables convenient clinical sampling from the rectum to support non-invasive testing for conditions such as colorectal cancer and IBD. The company is developing a portfolio of in vitro diagnostic tests based on this platform. Products are manufactured under ISO 13485 quality standards. Clinical results have not been published but products are positioned for early detection with a focus on accuracy and affordability.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Origin Sciences.